FINWIRES · TerminalLIVE
FINWIRES

HKG:2105

3 stories mentioning HKG:2105

Every FINWIRES story that references HKG:2105, newest first.

Asia

Hong Kong Stocks Fall as U.S.-Iran Hostilities Escalate; WuXi AppTec Gains on Buyback Plan

Hong Kong stocks declined on Wednesday as Iran and the United States engaged in their biggest exchange of hostilities since a ceasefire was agreed in April.The Hang Seng Index fell 0.6%, or 157.94 points, to close at 24,407.96, while the Hang Seng China Enterprises Index was little changed, slipping 5.86 points, to finish at 8,318.73.Iran's Revolutionary Guards said they launched missile and drone attacks on U.S. military facilities in Jordan, Kuwait, and Bahrain, describing the strikes as retaliation for Washington's recent attacks against Iranian targets near the Strait of Hormuz.The attacks followed comments by U.S. President Donald Trump that Iran had shot down an Apache helicopter near the strategic waterway a day earlier.Meanwhile, closer to home, China's producer price inflation accelerated to 3.9% in May from 2.8% in April, matching market expectations.Annual consumer inflation, however, remained at 1.2%, below the consensus forecast of 1.3%, while core inflation, which excludes food and energy prices, eased to 1.1% from 1.2% a month earlier.In corporate news, Laekna (HKG:2105) closed nearly 2% lower after granting Vasque Bio exclusive rights to develop and commercialize its cancer drug candidate LAE118 outside Greater China under a licensing agreement.WuXi AppTec (HKG:2359, SHA:603259) gained over 3% in Hong Kong after its board approved a proposed buyback of up to 1 billion yuan of A-shares.

Hang SengHKG:2105HKG:2359SHA:603259
Asia

Laekna Licenses Cancer Drug Candidate to Vasque Bio Outside Greater China

Laekna (HKG:2105) granted Vasque Bio exclusive rights to develop and commercialize its cancer drug candidate LAE118 outside Greater China under a licensing agreement, according to a Wednesday Hong Kong bourse filing.The biotechnology company will receive a $10 million upfront payment and is eligible for up to $517 million in development and sales milestone payments under the deal.Laekna will also have the right to acquire, at no additional cost, up to a high-teen-percentage stake in Vasque Bio's outstanding common stock, or to receive cash payments in lieu of the shares.In addition, the company is entitled to tiered royalties ranging from single-digit to double-digit percentages on future net sales of LAE118 in the licensed territory.It may also receive additional payments tied to certain strategic transactions involving the drug candidate, the filing said.Shares of Laekna were down over 4% in Wednesday morning trade.

HKG:2105
Asia

Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial

Laekna (HKG:2105) said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.The firm said it will submit a new drug application for LAE002 in China in the "near term."

HKG:2105